Перейти к контенту
Main image
Печать
OLOMOUCINE 1PC X 5MG
Кат. №: 495620-5MG
Производитель: Sigma-Aldrich
Кол-во:
Фасовка:
Цена по запросу
Товар оформляется под заказ
Печать
OLOMOUCINE 1PC X 5MG
Main image
Кат. №: 495620-5MG
Производитель: Sigma-Aldrich
Кол-во:
Фасовка:
Цена по запросу
Товар оформляется под заказ
Main image
Печать
OLOMOUCINE 1PC X 5MG
Кат. №: 495620-5MG
Производитель: Sigma-Aldrich
Кол-во:
Фасовка:
Цена по запросу
Товар оформляется под заказ
Description General description A purine derivative that acts as a potent, reversible and selective inhibitor of p34cdk1/cyclin B (IC50 = 7 µM) and related kinases including p33cdk2/cyclin A (IC50 = 7 µM), p33cdk2/cyclin E (IC50 = 7 µM), p33cdk5/p35 (IC50 = 3 µM), and p44 MAP kinase (IC50 = 25 µM). Acts by competing for the ATP binding domain of the kinase. Exhibits reduced sensitivity towards related kinases, p34cdk4/cyclin D (IC50 > 1 mM), and p40cdk6/cyclin D3 (IC50 > 250 µM). Does not significantly affect the activity of other protein kinases at 1 mM. Known to inhibit DNA synthesis in interleukin-2-stimulated T lymphocytes and trigger G1 arrest similar to that observed in interleukin-2-deprived cells. Also used to synchronize cells in G1. A 50 mM (5 mg/336 µl) solution of Olomoucine (Cat. No. 495624) in DMSOis also available. A purine derivative that acts as a potent, reversible, and selective inhibitor of p34cdc2/cyclin B (IC50 = 7 µM) and related kinases, including p33cdk2/cyclin A (IC50 = 7 µM), p33cdk2/cyclin E (IC50 = 7 µM), p33cdk5/p35 (IC50 = 3 µM), and p44MAPK (IC50 = 25 µM). Acts by competing for the ATP binding domain of the kinase. Exhibits reduced sensitivity towards related kinases, p34cdk4/cyclin D1 (IC50 > 1000 µM) and p40cdk6/cyclin D3 (IC50 > 250 µM). Does not significantly affect the activity of other protein kinases even at 1 mM concentrations. Known to inhibit DNA synthesis in interleukin-2 stimulated T lymphocytes and triggers G1 arrest similar to that observed in interleukin-2 deprived cells. Also used to synchronize cells in G1. Packaging 1, 5 mg in Plastic ampoule Biochem/physiol Actions Cell permeable: yes Primary Target p34cdk1/cyclin B Product competes with ATP. Reversible: yes Target IC50: 7 µM, 7 µM, 7 µM, 3 µM, 25 µM against p34cdk1/cyclin B, p33cdk2/cyclin A, p33cdk2/cyclin E, p33cdk5/p35, and p44 MAP kinase, respectively Warning Toxicity: Standard Handling (A) Reconstitution Following reconstitution, aliquot and freeze (-20°C). DMSO stock solutions are stable for up to 6 months at -20°C. Other Notes Abraham, R.T., et al. 1995. Biol. Cell 83, 105. Mistelli, T., and Warren, G. 1995. J. Cell Sci. 108, 2715. Glab, N., et al. 1994. FEBS Lett. 353, 207. Veselý, J., et al. 1994. Eur. J. Biochem.224, 771.
Related Categories
Cell Biology, Cell Signaling and Neuroscience, Cyclin-Dependent Kinase (CDK), Kinase/Phosphatase Biology, Serine/Threonine Kinase Biology, Serine/Threonine Kinase Inhibitors More... Quality Level
Дорогой клиент, на сайте внедрена нейросеть для сбора информации о товаре. Это может привести к незначительным расхождениям в характеристиках продукции.
Description General description A purine derivative that acts as a potent, reversible and selective inhibitor of p34cdk1/cyclin B (IC50 = 7 µM) and related kinases including p33cdk2/cyclin A (IC50 = 7 µM), p33cdk2/cyclin E (IC50 = 7 µM), p33cdk5/p35 (IC50 = 3 µM), and p44 MAP kinase (IC50 = 25 µM). Acts by competing for the ATP binding domain of the kinase. Exhibits reduced sensitivity towards related kinases, p34cdk4/cyclin D (IC50 > 1 mM), and p40cdk6/cyclin D3 (IC50 > 250 µM). Does not significantly affect the activity of other protein kinases at 1 mM. Known to inhibit DNA synthesis in interleukin-2-stimulated T lymphocytes and trigger G1 arrest similar to that observed in interleukin-2-deprived cells. Also used to synchronize cells in G1. A 50 mM (5 mg/336 µl) solution of Olomoucine (Cat. No. 495624) in DMSOis also available. A purine derivative that acts as a potent, reversible, and selective inhibitor of p34cdc2/cyclin B (IC50 = 7 µM) and related kinases, including p33cdk2/cyclin A (IC50 = 7 µM), p33cdk2/cyclin E (IC50 = 7 µM), p33cdk5/p35 (IC50 = 3 µM), and p44MAPK (IC50 = 25 µM). Acts by competing for the ATP binding domain of the kinase. Exhibits reduced sensitivity towards related kinases, p34cdk4/cyclin D1 (IC50 > 1000 µM) and p40cdk6/cyclin D3 (IC50 > 250 µM). Does not significantly affect the activity of other protein kinases even at 1 mM concentrations. Known to inhibit DNA synthesis in interleukin-2 stimulated T lymphocytes and triggers G1 arrest similar to that observed in interleukin-2 deprived cells. Also used to synchronize cells in G1. Packaging 1, 5 mg in Plastic ampoule Biochem/physiol Actions Cell permeable: yes Primary Target p34cdk1/cyclin B Product competes with ATP. Reversible: yes Target IC50: 7 µM, 7 µM, 7 µM, 3 µM, 25 µM against p34cdk1/cyclin B, p33cdk2/cyclin A, p33cdk2/cyclin E, p33cdk5/p35, and p44 MAP kinase, respectively Warning Toxicity: Standard Handling (A) Reconstitution Following reconstitution, aliquot and freeze (-20°C). DMSO stock solutions are stable for up to 6 months at -20°C. Other Notes Abraham, R.T., et al. 1995. Biol. Cell 83, 105. Mistelli, T., and Warren, G. 1995. J. Cell Sci. 108, 2715. Glab, N., et al. 1994. FEBS Lett. 353, 207. Veselý, J., et al. 1994. Eur. J. Biochem.224, 771.
Related Categories
Cell Biology, Cell Signaling and Neuroscience, Cyclin-Dependent Kinase (CDK), Kinase/Phosphatase Biology, Serine/Threonine Kinase Biology, Serine/Threonine Kinase Inhibitors More... Quality Level
Дорогой клиент, на сайте внедрена нейросеть для сбора информации о товаре. Это может привести к незначительным расхождениям в характеристиках продукции.